Profile Response Detail

Molecular Profile MET amp
Therapy SAR125844
Indication/Tumor Type Advanced Solid Tumor
Response Type predicted - sensitive
Create By csp
Update By djd

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET amp Advanced Solid Tumor predicted - sensitive SAR125844 Phase I Actionable In a Phase I trial, SAR125844 treatment in advanced solid tumor patients harboring a MET amplification was well-tolerated and resulted in a partial response in 17% (5/29) of patients, including patients with non-small cell lung carcinoma, and stable disease in 59% (17/29) of patients (PMID: 29145039; NCT01391533). detail... 29145039
PubMed Id Reference Title Details
A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results. Full reference...
(29145039) A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. Full reference...